TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Vera Therapeutics ( (VERA) ).
On November 6, 2025, Vera Therapeutics announced significant results from its ORIGIN Phase 3 trial of atacicept for IgA nephropathy, presented at the American Society of Nephrology Kidney Week and published in The New England Journal of Medicine. The trial showed a 46% reduction in proteinuria and favorable safety outcomes, positioning atacicept as a promising treatment option and potentially impacting the company’s market position positively.
The most recent analyst rating on (VERA) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.
Spark’s Take on VERA Stock
According to Spark, TipRanks’ AI Analyst, VERA is a Underperform.
Vera Therapeutics’ overall stock score is driven by ongoing financial challenges, including consistent losses and negative cash flows, despite a strong equity position. Technical analysis indicates bearish momentum, with the stock underperforming key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on VERA stock, click here.
More about Vera Therapeutics
Vera Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for immunological and kidney diseases. The company is particularly involved in creating therapies for IgA nephropathy, a chronic kidney disease.
Average Trading Volume: 1,565,761
Technical Sentiment Signal: Sell
Current Market Cap: $1.55B
Find detailed analytics on VERA stock on TipRanks’ Stock Analysis page.